NESS ZIONA, Israel, May 11, 2017 /PRNewswire/ --
Yehiel Tal, CollPlant's Chief Executive Officer, noted, "Over the last several months, we have substantially ramped up our activities in the 3D printing field leveraging biological ink that we are developing based on our rhCollagen technology. The collagen protein is a key building block in connective tissues in the human body, and therefore is ideal for use as biological ink. In particular, our rhCollagen is especially suitable for use in humans, due to its superior homogeneity, its high safety profile and the fact that it does not cause an immunological reaction. We are currently developing a number of formulations of biological ink for various indications, and are working with several large international companies, with the aim of collaborating in the development of organs and tissues printing."
According to the U.S. Department of Health and Human Services, the number of people in the United States waiting for a transplant of a critical, life-saving organ such as a kidney, liver or pancreas, is approximately 118,000, and the organ transplant waiting list grows every year. BioInk is a significant component of the burgeoning 3D bioprinting market, which is expected to grow to approximately USD 1.8 billion by 2022, and to increase substantially as the printing technology, and all its components, continue to mature.
CollPlant is a regenerative medicine company leveraging its proprietary, plant-based recombinant human collagen (rhCollagen) technology for the development and commercialization of tissue repair products, initially for the orthobiologics, 3D Bio-printing of tissue and organs, and advanced wound care markets. The Company's cutting-edge technology is designed to generate and process proprietary rhCollagen, among other patent-protected recombinant proteins. Given that CollPlant's rhCollagen is identical to the type I collagen produced by the human body, it offers significant advantages compared to currently marketed tissue-derived collagen, including improved biofunctionality, superior homogeneity and reduced risk of immune response. The Company's broad development pipeline includes biomaterials indicated for orthopedics and advanced wound healing. Lead products include: Vergenix™STR (Soft Tissue Repair Matrix), for the treatment of tendinopathy; and Vergenix™FG (Flowable Gel) wound filler, for treatment of acute and chronic wounds. CollPlant's business strategy includes proprietary development and manufacture of tissue repair products and their commercialization and distribution, together with leading third parties, alongside alliances with leading companies for joint development, manufacture and marketing of additional products.
For more information about CollPlant, visit http://www.collplant.com
Contact at CollPlant: Eran Rotem Chief Financial Officer Tel: + 972-73-2325600/612 Email: Eran@collplant.com Contact at Rx Communications Group, LLC Paula Schwartz (for US Investors) Managing Director Tel: 917-322-2216 Email: email@example.com
Subscribe to our Free Newsletters!
A patient's struggle with Issacs' syndrome with no cure. Also known as neuromyotonia it is a rare ...
Inguinal hernia surgery is a procedure to repair a weak spot or defect in the lower wall of the ...
Hypopituitarism is a rare disorder resulting from decreased secretion of one or more of the ...View All